Literature DB >> 2860044

European Cooperative Crohn's Disease Study (ECCDS): clinical features and natural history.

H J Steinhardt, K Loeschke, H Kasper, K H Holtermüller, H Schäfer.   

Abstract

In the European Cooperative Crohn's Disease Study patients from 14 centers were included in whom diagnosis was made within 2 years before study entry on the basis of generally accepted radiological, endoscopical and/or histological criteria or a combination of all. Reasons for exclusion were: diagnosis older than 2 years in patients who did not require active treatment, age less than 18 years, duration of symptoms less than 3 months, presence of complications which potentially required emergency surgery. Data on clinical features were obtained in 633 patients, of whom 452 were eligible to participate in the study. In 110 patients randomized to placebo the natural course of Crohn's disease was studied. Patients with ileocolonic involvement were younger than patients with either colonic or small intestinal involvement only. Classic ileitis terminalis was present in 14% of the patients. 49% of the patients had combined involvement of both the small and large intestine. 30% of patients had only small intestinal involvement, and in 21% colonic disease was present. Small intestinal involvement was associated with a significantly lower Crohn's Disease Activity Index (CDAI) than other anatomical locations of the disease. Perianal disease was more often associated with colonic than with small intestinal involvement. 60% of placebo patients with active disease at entry achieved at least a transient remission within the initial 5 months of study. After 2 years, 23% of patients with active disease at entry and 68% of patients with quiescent disease had reached or maintained a remission, respectively. By stepwise multiple linear regression analysis long duration of disease between diagnosis and randomization, normal serum albumin and combined involvement of small intestine and colon were identified as predictors of a more favorable outcome of patients treated with placebo. In contrast, extensive small bowel disease, treatment with steroids and bowel resection prior to study entry correlated with a less favorable outcome. However, by life table analysis outcome of previously untreated and treated patients in the placebo group was similar.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2860044     DOI: 10.1159/000199186

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  18 in total

Review 1.  [What is the role of nutrition in Crohn disease? A contribution to the importance of dietary therapy in regional enteritis].

Authors:  E Nagel; H Canzler; R Pichlmayr
Journal:  Langenbecks Arch Chir       Date:  1991

2.  Small bowel involvement in Crohn's disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis.

Authors:  W A Voderholzer; J Beinhoelzl; P Rogalla; S Murrer; G Schachschal; H Lochs; M-A Ortner
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

3.  Clinical relapse of Crohn's disease under standardized conservative treatment and after excisional surgery.

Authors:  E Dirks; H Goebell; K Schaarschmidt; S Förster; E Quebe-Fehling; F W Eigler
Journal:  Dig Dis Sci       Date:  1989-12       Impact factor: 3.199

4.  Clinical profile and predictors of disease behavior and surgery in Indian patients with Crohn's disease.

Authors:  Ashish Goel; Amit Kumar Dutta; Anna B Pulimood; Anu Eapen; Ashok Chacko
Journal:  Indian J Gastroenterol       Date:  2013-02-16

Review 5.  Capsule endoscopy in Crohn's disease: are we seeing any better?

Authors:  David Hudesman; Jonathan Mazurek; Arun Swaminath
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

6.  European survey of fertility.

Authors:  J Purrmann; B Miller; G Strohmeyer
Journal:  Gut       Date:  1986-12       Impact factor: 23.059

7.  Roles of double-balloon endoscopy in the diagnosis and treatment of Crohn's disease: a multicenter experience.

Authors:  Jumpei Kondo; Hideki Iijima; Takashi Abe; Masato Komori; Satoshi Hiyama; Toshifumi Ito; Akihiro Nakama; Kouhei Tominaga; Mitsuhiko Kubo; Kunio Suzuki; Yoshihisa Iwanaga; Ryoichi Ebara; Akira Takeda; Shingo Tsuji; Tsutomu Nishida; Shusaku Tsutsui; Masahiko Tsujii; Norio Hayashi
Journal:  J Gastroenterol       Date:  2010-02-20       Impact factor: 7.527

8.  Double-balloon enteroscopy in Crohn's disease patients suspected of small bowel activity: findings and clinical impact.

Authors:  P B F Mensink; M J Groenen; H R van Buuren; E J Kuipers; C J van der Woude
Journal:  J Gastroenterol       Date:  2009-03-07       Impact factor: 7.527

9.  Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

Authors:  T Sahmoud; G Hoctin-Boes; R Modigliani; A Bitoun; J F Colombel; J C Soule; C Florent; J P Gendre; E Lerebours; R Sylvester
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

10.  Treatment of Fistulizing Crohn's Disease in Children.

Authors:  Alka Goyal; Evan P. Nadler; Henri R. Ford; David J. Keljo
Journal:  Curr Treat Options Gastroenterol       Date:  2003-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.